

RLL-318WO

In the Claims:

Please amend claims 3, 6-11, 18-19, 33, 41-42, 47-53 and cancel claims 20-27, 30, 34-38, 43-44 as follows:

1. (original) A calcium salt of rabeprazole.
2. (original) The salt of claim 1, which is rabeprazole hemicalcium.
3. (currently amended) The salt of claim 1 or 2, which is in a crystalline form.
4. (original) The salt of claim 3, which is an alcohol solvate.
5. (original) The salt of claim 4, which is a methanol solvate.
6. (currently amended) The salt of claim 1 or 2, which is in a substantially amorphous form.
7. (currently amended) The salt of claim 1 or 2, which is hydrated.
8. (currently amended) The ~~salt crystalline form of rabeprazole calcium~~ of claim 3, wherein the rabeprazole calcium has the X-ray diffraction pattern of Figure 1.
9. (currently amended) The ~~salt crystalline form of rabeprazole calcium~~ of claim 3, wherein the rabeprazole calcium has the infrared spectrum of Figure 2.
10. (currently amended) The ~~salt amorphous form of rabeprazole calcium~~ of claim 6, wherein the rabeprazole calcium has the X-ray diffraction pattern of Figure 4.
11. (currently amended) The ~~salt amorphous form of rabeprazole calcium~~ of claim 6, wherein the rabeprazole calcium has the infrared spectrum of Figure 5.
12. (original) A pharmaceutical composition comprising:
a therapeutically effective amount of rabeprazole calcium; and one or more pharmaceutically acceptable carriers, excipients or diluents.
13. (original) A process for the preparation of rabeprazole calcium, the process comprising:

RLL-318WO

contacting rabeprazole free base or rabeprazole sodium with a calcium salt of an acid in a suitable solvent; and

isolating the rabeprazole calcium from the solution thereof by the removal of the solvent.

14. (original) The process of claim 13, wherein the calcium salt of an acid is a salt of an inorganic acid.

15. (original) The process of claim 14, wherein the calcium salt comprises one or more of calcium chloride, calcium nitrate, calcium sulphate, calcium phosphate, calcium carbonate, and calcium dihydrogenphosphate.

16. (original) The process of claim 13, wherein the calcium salt of an acid is a salt of an organic acid.

17. (original) The process of claim 16, wherein the calcium salt comprises one or more of calcium oxalate, calcium acetate, calcium lactate, calcium succinate, calcium citrate, and calcium tartrate.

18. (currently amended) The process of claim claims 13, wherein the solvent comprises one or more of water, lower alkanol, ketone, ester, ether, nitrile, hydrocarbon, dipolar aprotic solvent, or mixtures thereof.

19. (currently amended) The process of claim 18, wherein the the lower alkanol comprises one or more of primary, secondary and tertiary alcohol having from one to six carbon atoms.

20.-27. (cancelled)

28. (original) The process of claim 13, further comprising adding a base if rabeprazole free base is used as a starting material.

29. (original) The process of claim 28, wherein the base comprises one or more of an alkali metal hydroxide, alkali metal carbonate and alkali metal bicarbonate.

30. (cancelled)

RLL-318WO

31. (original) The process of claim 13, wherein the rabeprazole calcium precipitates out spontaneously from the solvent.
32. (original) The process of claim 13, wherein removing the solvent comprises one or more of filtration, filtration under vacuum, decantation, and centrifugation.
33. (currently amended) The process of claim 13, wherein one or more of rabeprazole hemicalcium, a crystalline form of rabeprazole calcium, an alcohol solvate, a substantially amorphous form of rabeprazole calcium, or a hydrate of rabeprazole calcium is isolated from the solution.
- 34.-38. (cancelled)
39. (original) The process of claim 13, further comprising additional drying of the product obtained.
40. (original) The process of claim 13, further comprising forming the product obtained into a finished dosage form.
41. (currently amended) The process of claim 13, wherein the rabeprazole calcium has the X-ray diffraction pattern of Figure 1 or Figure 4.
42. (currently amended) The process of claim 13, wherein the rabeprazole calcium has the infrared spectrum of Figure 2 or Figure 5.
- 43.-44. (cancelled)
45. (original) A method for treating or preventing gastrointestinal ulcers, which comprises administering to a patient in need thereof an effective amount of rabeprazole calcium.
46. (original) The method of claim 45, wherein the rabeprazole calcium is used for healing of erosive or ulcerative gastroesophageal reflux disease (GERD); maintenance of healing of erosive or ulcerative GERD; healing of duodenal ulcer; or treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
47. (currently amended) The method of claim 45, ~~or 46~~, wherein the rabeprazole calcium is comprises rabeprazole hemicalcium.

RLL-318WO

48. (currently amended) A The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is intended for use in the treatment or prevention of gastrointestinal ulcers ~~comprising an effective amount of rabeprazole calcium and pharmaceutically acceptable excipients.~~ (currently amended) The pharmaceutical composition of claim 12 48, wherein the rabeprazole calcium is rabeprazole hemicalcium.

49. (currently amended) The pharmaceutical composition of claim 12 48, ~~or 49~~, wherein a crystalline form of the rabeprazole calcium is used.

50. (currently amended) The pharmaceutical composition of claim 12 48, ~~or 49~~, wherein an alcohol solvate of the rabeprazole calcium is used.

51. (currently amended) The pharmaceutical composition of claim 12 48, ~~or 49~~, wherein a substantially amorphous form of the rabeprazole calcium is used.

52. (currently amended) The pharmaceutical composition of claim 12 48, ~~or 49~~, wherein a hydrate of the rabeprazole calcium is used.